InvestorsHub Logo
Followers 234
Posts 26887
Boards Moderated 0
Alias Born 01/12/2013

Re: DewDiligence post# 575

Tuesday, 01/21/2020 11:23:28 PM

Tuesday, January 21, 2020 11:23:28 PM

Post# of 625
Dew- Gilead CEO expresses interest in NASH and cancer assets, Dealreporter says When pressed by an analyst during its Q3 earnings call, Gilead Sciences' (GILD) CEO Daniel O'Day said the company is looking carefully in the areas of nonalcoholic steatohepatitis and in oncology, said Dealreporter, according to contacts. If Gilead "is serious about wading into NASH, which would build on its liver franchise-building expertise in HCV, Intercept Pharmaceuticals (ICPT) could be a name to watch," the deal-focused publication stated, according to contacts.

Read more at:
https://thefly.com/landingPageNews.php?id=2981475

Also:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137563501

My point, both AMRN & ICPT are key to GILD NASH success.

BB

If you're not good at being yourself, then maybe that's being yourself!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ICPT News